Actively Recruiting
Evaluating Safety and Immune Response of a 21-valent Pneumococcal Vaccine Compared to a Licensed 20-valent Vaccine in Healthy Infants
Led by Sanofi · Updated on 2026-10-05
2195
Participants Needed
25
Research Sites
51 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating three lots of an investigational 21-valent pneumococcal conjugate vaccine PCV21 to see if they produce similar immune responses and are safe compared to a licensed 20-valent pneumococcal vaccine 20vPCV in healthy infants aged approximately 2 months. This phase 3, randomized, modified double-blind study aims to measure antibody development and safety of these vaccines as part of routine pediatric immunization. Participants will receive four doses of either one of three PCV21 vaccine lots or the 20vPCV comparator at about 2, 4, 6, and 12 months of age through intramuscular injections. The study includes two cohorts Cohort A, which is randomized to three PCV21 groups or one 20vPCV group, and Cohort B, randomized to three PCV21 groups only. All vaccinations are co-administered with routine pediatric vaccines as per local recommendations. Throughout the study, participants will attend six visits spaced over approximately 17 months. Researchers will collect blood samples to measure immune response 30 days after the third vaccine dose and monitor immediate and longer-term adverse events after each injection. Safety and immunogenicity are assessed through questionnaires, medical evaluations, and lab tests, with monitoring continuing up to six months after the final vaccine dose.
CONDITIONS
Brief Title
Lot-to-lot Consistency Study of a 21-valent Pneumococcal Conjugate Vaccine in Healthy Infants From 2 Months of Age
Research Team
T
Trial Transparency email recommended (Toll free for US & Canada)
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here